Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Other Announcement

Solara Active Pharma Sciences Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026. This disclosure details equity ownership across various investor categories.

Solara Active Pharma Sciences Earnings Call Transcript: Key Takeaways

Solara delivered its best profitability in five years despite ongoing Ibuprofen pricing and raw material challenges.

Solara Active Pharma Sciences Investor Presentation: Key Takeaways

Solara's Q2 FY27 delivered record EBITDA and PAT in five years, driven by 33% revenue growth. Base business strength offset Ibuprofen headwinds, which is now nearing breakeven.

Solara Active Pharma Sciences Employee Stock Options

Solara Active Pharma Sciences Limited allotted 8,300 equity shares under its 2018 ESOP plan. The exercise of these options realized Rs. 0.31 Crore for the company.

Value

₹0.31 Cr

Solara Active Pharma Sciences Q2 FY27 Results: Turns Profitable, Net Profit ₹28.5 Cr

Solara Active Pharma Sciences Ltd reported revenue from operations of ₹417.3 Cr (+33.1% YoY) and net profit of ₹28.5 Cr for Q2 FY27.

Key figure

Net profit ₹28.5 Cr